RU96105930A - IONTOPHORETIC DELIVERY OF ANTIGRIBULAR PREPARATION - Google Patents
IONTOPHORETIC DELIVERY OF ANTIGRIBULAR PREPARATIONInfo
- Publication number
- RU96105930A RU96105930A RU96105930/14A RU96105930A RU96105930A RU 96105930 A RU96105930 A RU 96105930A RU 96105930/14 A RU96105930/14 A RU 96105930/14A RU 96105930 A RU96105930 A RU 96105930A RU 96105930 A RU96105930 A RU 96105930A
- Authority
- RU
- Russia
- Prior art keywords
- formula
- active ingredient
- periods
- alkyl
- range
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- -1 chlorine ions Chemical class 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229910052709 silver Inorganic materials 0.000 claims 2
- 239000004332 silver Substances 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- QVSXOXCYXPQXMF-UHFFFAOYSA-N Alniditan Chemical compound C1CC2=CC=CC=C2OC1CNCCCNC1=NCCCN1 QVSXOXCYXPQXMF-UHFFFAOYSA-N 0.000 claims 1
- 229940089114 Drug Delivery Device Drugs 0.000 claims 1
- 206010027599 Migraine Diseases 0.000 claims 1
- 208000008085 Migraine Disorders Diseases 0.000 claims 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M Silver chloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 238000001962 electrophoresis Methods 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000002154 ionophoretic Effects 0.000 claims 1
- 230000001057 ionotropic Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 230000000737 periodic Effects 0.000 claims 1
- 229920001059 synthetic polymer Polymers 0.000 claims 1
Claims (24)
его фармацевтически приемлемую соль присоединения кислоты или его стереохимически изомерную форму, где
R1 обозначает водород или C1-6 - алкил;
R2 обозначает водород или C1-6 - алкил, C3-6 - алкенил или C3-6 - алкинил;
R3 обозначает водород или C1-6алкил; или
R2 и R3, взятые вместе, образуют бивалентый радикал формулы - (CH2)m, где m равно 4 или 5; или
R1 и R2, взятые вместе, образуют бивалентный радикал формулы -CH=CH- или формулы -(CH2)n), где n равно 2, 3 или 4; или
R3 может обозначать связь, когда R1 и R2, взятые вместе, образуют бивалентный радикал формулы -CH=CH-CH=;
R4 и R5, каждый независимо обозначают водород или C1-6 алкил;
Alk1 обозначает бивалентный C1-3 алкандиильный радикал;
Alk2 обозначает бивалентный C2-15 алкандиильный радикал;
R6 и R7 каждый независимо обозначают водород, галоген, C1-6 алкил, C3-6 алкенил, C3-6 алкинил, гидрокси, C1-6 алкилокси или циано.Ionotropic drug delivery device, characterized in that it contains, as an active ingredient, a compound of the formula
its pharmaceutically acceptable acid addition salt or stereochemically isomeric form thereof, wherein
R 1 is hydrogen or C 1-6 alkyl;
R 2 is hydrogen or C 1-6 alkyl, C 3-6 alkenyl or C 3-6 alkynyl;
R 3 is hydrogen or C 1-6 alkyl; or
R 2 and R 3 taken together form a bivalent radical of the formula - (CH 2 ) m , where m is 4 or 5; or
R 1 and R 2 taken together form a bivalent radical of the formula —CH═CH— or formula - (CH 2 ) n ), where n is 2, 3 or 4; or
R 3 may denote a bond when R 1 and R 2 taken together form a bivalent radical of the formula —CH═CH — CH =;
R 4 and R 5 each independently represent hydrogen or C 1-6 alkyl;
Alk 1 is a bivalent C 1-3 alkanediyl radical;
Alk 2 is a bivalent C 2-15 alkanediyl radical;
R 6 and R 7 are each independently hydrogen, halogen, C 1-6 alkyl, C 3-6 alkenyl, C 3-6 alkynyl, hydroxy, C 1-6 alkyloxy, or cyano.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93202523.2 | 1993-08-27 | ||
EP93202523 | 1993-08-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU96105930A true RU96105930A (en) | 1998-10-27 |
RU2166315C2 RU2166315C2 (en) | 2001-05-10 |
Family
ID=8214068
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU96105930/14A RU2166315C2 (en) | 1993-08-27 | 1994-08-19 | Iontophoretic delivery of antimigraine preparation |
Country Status (28)
Country | Link |
---|---|
US (1) | US5674871A (en) |
EP (1) | EP0719138B1 (en) |
JP (1) | JP2921987B2 (en) |
KR (1) | KR100187632B1 (en) |
CN (1) | CN1096857C (en) |
AT (1) | ATE176591T1 (en) |
AU (1) | AU687876B2 (en) |
BR (1) | BR9407522A (en) |
CA (1) | CA2168449A1 (en) |
CZ (1) | CZ290473B6 (en) |
DE (1) | DE69416522T2 (en) |
DK (1) | DK0719138T3 (en) |
ES (1) | ES2129668T3 (en) |
FI (1) | FI960887A (en) |
GR (1) | GR3029920T3 (en) |
HR (1) | HRP940481A2 (en) |
HU (1) | HUT75062A (en) |
IL (1) | IL110784A (en) |
MY (1) | MY111022A (en) |
NO (1) | NO317628B1 (en) |
NZ (1) | NZ273304A (en) |
PH (1) | PH31437A (en) |
PL (1) | PL176290B1 (en) |
RU (1) | RU2166315C2 (en) |
SG (1) | SG50469A1 (en) |
SI (1) | SI9400333B (en) |
WO (1) | WO1995005815A1 (en) |
ZA (1) | ZA946533B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5853383A (en) * | 1995-05-03 | 1998-12-29 | Alza Corporation | Preparation for formulations for electrotransport drug delivery |
US7137975B2 (en) * | 2001-02-13 | 2006-11-21 | Aciont, Inc. | Method for increasing the battery life of an alternating current iontophoresis device using a barrier-modifying agent |
KR100856693B1 (en) * | 2001-04-04 | 2008-09-04 | 알자 코포레이션 | Transdermal electrotransport delivery device including an antimicrobial compatible reservoir composition |
WO2002089803A1 (en) * | 2001-05-07 | 2002-11-14 | Sankyo Company, Limited | Composition for iontophoresis |
US8016811B2 (en) * | 2003-10-24 | 2011-09-13 | Altea Therapeutics Corporation | Method for transdermal delivery of permeant substances |
US20050220439A1 (en) * | 2004-03-19 | 2005-10-06 | Carton Owen A | Interactive multimedia system and method |
WO2007009462A2 (en) * | 2005-07-15 | 2007-01-25 | Region Hovedstaden V/Glostrup Hospital | Treatment of migraine and headaches |
CN104138634B (en) * | 2006-04-13 | 2016-09-07 | 梯瓦制药国际有限责任公司 | The transdermal methods of delivery of anti-migraine compounds and system |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3740549B2 (en) * | 1990-03-30 | 2006-02-01 | アルザ・コーポレーション | Apparatus and method for drug administration by ion permeation therapy |
SI9300097B (en) * | 1992-02-27 | 2001-12-31 | Janssen Pharmaceutica Nv | (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines |
-
1994
- 1994-07-15 PH PH48643A patent/PH31437A/en unknown
- 1994-08-19 CN CN94193196A patent/CN1096857C/en not_active Expired - Fee Related
- 1994-08-19 CA CA002168449A patent/CA2168449A1/en not_active Abandoned
- 1994-08-19 RU RU96105930/14A patent/RU2166315C2/en not_active IP Right Cessation
- 1994-08-19 KR KR1019960700410A patent/KR100187632B1/en not_active IP Right Cessation
- 1994-08-19 AT AT94926855T patent/ATE176591T1/en not_active IP Right Cessation
- 1994-08-19 NZ NZ273304A patent/NZ273304A/en unknown
- 1994-08-19 HU HU9600471A patent/HUT75062A/en unknown
- 1994-08-19 SG SG1996002184A patent/SG50469A1/en unknown
- 1994-08-19 DK DK94926855T patent/DK0719138T3/en active
- 1994-08-19 WO PCT/EP1994/002764 patent/WO1995005815A1/en active IP Right Grant
- 1994-08-19 JP JP7507338A patent/JP2921987B2/en not_active Expired - Fee Related
- 1994-08-19 AU AU76542/94A patent/AU687876B2/en not_active Ceased
- 1994-08-19 DE DE69416522T patent/DE69416522T2/en not_active Expired - Fee Related
- 1994-08-19 ES ES94926855T patent/ES2129668T3/en not_active Expired - Lifetime
- 1994-08-19 PL PL94313255A patent/PL176290B1/en not_active IP Right Cessation
- 1994-08-19 BR BR9407522A patent/BR9407522A/en not_active Application Discontinuation
- 1994-08-19 US US08/586,700 patent/US5674871A/en not_active Expired - Fee Related
- 1994-08-19 EP EP94926855A patent/EP0719138B1/en not_active Expired - Lifetime
- 1994-08-19 CZ CZ1996570A patent/CZ290473B6/en not_active IP Right Cessation
- 1994-08-25 MY MYPI94002234A patent/MY111022A/en unknown
- 1994-08-25 IL IL11078494A patent/IL110784A/en not_active IP Right Cessation
- 1994-08-26 ZA ZA946533A patent/ZA946533B/en unknown
- 1994-08-26 SI SI9400333A patent/SI9400333B/en not_active IP Right Cessation
- 1994-08-26 HR HR93.202.523.2A patent/HRP940481A2/en not_active Application Discontinuation
-
1996
- 1996-02-26 FI FI960887A patent/FI960887A/en not_active Application Discontinuation
- 1996-02-26 NO NO19960769A patent/NO317628B1/en unknown
-
1999
- 1999-04-07 GR GR990401012T patent/GR3029920T3/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0404807B1 (en) | Deprenyl for systemic transdermal administration | |
AU2006201898C1 (en) | Transdermal electrotransport delivery device including an antimicrobial compatible reservoir composition | |
US20050234389A1 (en) | Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds | |
JP2001070459A (en) | Composition for iontophoresis and device structure | |
JP3224814B2 (en) | Reduction or prevention of skin irritation by drugs | |
JP2007314562A (en) | Composition and method for enhancing transdermal electrotransport agent delivery | |
RU96105930A (en) | IONTOPHORETIC DELIVERY OF ANTIGRIBULAR PREPARATION | |
WO2000018369A1 (en) | Iontophoretic devices comprising piperidin derivatives | |
SI9400333B (en) | Oinophoretic delivery of an antimigraine drug | |
AU2005239833B2 (en) | Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds | |
JP6116790B2 (en) | Pharmaceutical composition for iontophoresis | |
Fabbri et al. | α-Adrenoceptor-mediated glucose release from perifused catfish hepatocytes | |
JPH03157332A (en) | Percutaneous partition of (plus)-(2s, 3s)-3- acetoxy-8-chloro-5-(2-dimethylaminoethyl)-2, 3-dihydro-2-(4-methoxyphenyl)-1, 5- benzothiazepine-4-(5h)-one | |
US20230143693A1 (en) | Iontophoretic composition for administering s-ketamine | |
Dawson et al. | Early and late effects of growth hormone on the rat diaphragm | |
JP6211033B2 (en) | Pharmaceutical composition for iontophoresis | |
JPH06336434A (en) | Skeletal muscle relaxant-percutaneous absorber | |
Gupta et al. | EFFECT OF VERAPAMIL, A CALCIUM CHANNEL ANTAGONIST ON INSULIN INDUCED HYPOGLYCAEMIA IN RATS AND RABBITS | |
EP0952869A1 (en) | Iontophoretic delivery of buprenorphine | |
WO2005020967A1 (en) | Electric drug transport preparation | |
KR20070012432A (en) | Transdermal iontophoretic delivery of piperazinyl-2(3h)-benzoxazolone compounds | |
JPH11124332A (en) | Percutaneous patch material containing 2,3-diketopiperazine derivative or its salt |